Gastrointestinal Manifestations of Cystic Fibrosis

Digestive Diseases and Sciences

Volumn 60, Issue 7, 2015, Pages 1903-1913

  Kelly, Thomas ^a   Buxbaum, James ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Choledocholithiasis; Cystic fibrosis; Gastrointestinal tract; Liver cirrhosis, biliary; Pancreatitis, chronic

Indexed keywords

ACUTE PANCREATITIS; APPENDICITIS; BACTERIAL OVERGROWTH; BILE DUCT DISEASE; BILIARY CIRRHOSIS; CHOLANGIECTASIS; CHOLELITHIASIS; CHRONIC PANCREATITIS; COLON DISEASE; CONSTIPATION; CYSTIC FIBROSIS; DIABETES MELLITUS; DIGESTIVE SYSTEM CANCER; DISTAL INTESTINAL OBSTRUCTION SYNDROME; FATTY LIVER; FIBROSING COLONOPATHY; FOCAL BILIARY CIRRHOSIS; GALLBLADDER DISEASE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEPATOBILIARY DISEASE; HUMAN; INTESTINE OBSTRUCTION; INTUSSUSCEPTION; LARGE BILE DUCT DISEASE; MECONIUM ILEUS; MICRO GALLBLADDER; NUTRITION; PANCREAS; PANCREAS CYST; PANCREAS INSUFFICIENCY; PEPTIC ULCER; PNEUMATOSIS INTESTINALIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM PROLAPSE; REVIEW; DIGESTIVE SYSTEM DISEASE; PATHOLOGY;

CYSTIC FIBROSIS; DIGESTIVE SYSTEM DISEASES; HUMANS;

EID: 84930819267     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3546-7     Document Type: Review

References (86)

1. Gabriel SE, Brigman KN, Koller BH, et al. Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science. 1994;266:107–109.
2. Wilschanski M, Durie PR. Patterns of GI disease in adulthood associated with mutations in the CFTR gene. Gut. 2007;56:1153–1163.
3. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352:1992–2001.
4. O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373:1891–1904.
5. Blackman SM, Deering-Brose R, McWilliams R, et al. Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. Gastroenterology. 2006;131:1030–1039.
6. Kopelman H, Durie P, Gaskin K, et al. Pancreatic fluid secretion and protein hyperconcentration in cystic fibrosis. N Engl J Med. 1985;312:329–334.
7. Shwachman H, Lebenthal E, Khaw KT. Recurrent acute pancreatitis in patients with cystic fibrosis with normal pancreatic enzymes. Pediatrics. 1975;55:86–95.
8. De Boeck K, Weren M, Proesmans M, et al. Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype. Pediatrics. 2005;115:e463–e469.
9. King LJ, Scurr ED, Murugan N, et al. Hepatobiliary and pancreatic manifestations of cystic fibrosis: MR imaging appearances. Radiographics. 2000;20:767–777.
10. Sharer N, Schwarz M, Malone G, et al. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med. 1998;339:645–652.
11. Waters DL, Dorney SF, Gaskin KJ, et al. Pancreatic function in infants identified as having cystic fibrosis in a neonatal screening program. N Engl J Med. 1990;322:303–308.
12. Proesmans M, De Boeck K. Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes. Eur J Pediatr. 2003;162:760–763.
13. Dodge JA, Turck D. Cystic fibrosis: nutritional consequences and management. Best Pract Res Clin Gastroenterol. 2006;20:531–546.
14. Agrons GA, Corse WR, Markowitz RI, et al. Gastrointestinal manifestations of cystic fibrosis: radiologic-pathologic correlation. Radiographics. 1996;16:871–893.
15. Liong SY, Awad D, Jones AM, et al. The adult cystic fibrosis patient with abdominal pain: what the radiologist needs to know. Clin Radiol. 2011;66:132–139.
16. Chaudry G, Navarro OM, Levine DS, et al. Abdominal manifestations of cystic fibrosis in children. Pediatr Radiol. 2006;36:233–240.
17. Andersen D. Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study. Am J Dis Chil. 1938;56:344–399.
18. Matel JL, Milla CE. Nutrition in cystic fibrosis. Semin Respir Crit Care Med. 2009;30:579–586.
19. Mousa HM, Woodley FW. Gastroesophageal reflux in cystic fibrosis: current understandings of mechanisms and management. Curr Gastroenterol Rep. 2012;14:226–235.
20. Cucchiara S, Santamaria F, Andreotti MR, et al. Mechanisms of gastro-oesophageal reflux in cystic fibrosis. Arch Dis Child. 1991;66:617–622.
21. Orenstein SR, Orenstein DM. Gastroesophageal reflux and respiratory disease in children. J Pediatr. 1988;112:847–858.
22. Eggermont E, Deboeck K. Small-intestinal abnormalities in cystic fibrosis patients. Eur J Pediatr. 1991;150:824–828.
23. Constantine S, Au VW, Slavotinek JP. Abdominal manifestations of cystic fibrosis in adults: a review. Australas Radiol. 2004;48:450–458.
24. Grossman H, Berdon WE, Baker DH. Gastrointestinal findings in cystic fibrosis. Am J Roentgenol Radium Ther Nucl Med. 1966;97:227–238.
25. Abramson SJ, Baker DH, Amodio JB, et al. Gastrointestinal manifestations of cystic fibrosis. Semin Roentgenol. 1987;22:97–113.
26. Robertson MB, Choe KA, Joseph PM. Review of the abdominal manifestations of cystic fibrosis in the adult patient. Radiographics. 2006;26:679–690.
27. Phelan MS, Fine DR, Zentlermunro PL, et al. Radiographic abnormalities of the duodenum in cystic fibrosis. Clin Radiol. 1983;34:573–577.
28. Ziegler MM. Meconium ileus. Curr Probl Surg. 1994;31:U731–U777.
29. Karimi A, Gorter RR, Sleeboom C, et al. Issues in the management of simple and complex meconium ileus. Pediatr Surg Int. 2011;27:963–968.
30. Gorter RR, Karimi A, Sleeboom C, et al. Clinical and genetic characteristics of meconium ileus in newborns with and without cystic fibrosis. J Pediatr Gastroenterol Nutr. 2010;50:569–572.
31. Fakhoury K, Durie PR, Levison H, et al. Meconium ileus in the absence of cystic fibrosis. Arch Dis Child. 1992;67:1204–1206.
32. Wyllie R. Gastrointestinal manifestations of cystic fibrosis. Clin Pediatr. 1999;38:735–738.
33. Casaccia G, Trucchi A, Nahom A, et al. The impact of cystic fibrosis on neonatal intestinal obstruction: the need for prenatal/neonatal screening. Pediatr Surg Int. 2003;19:75–78.
34. Lang I, Daneman A, Cutz E, et al. Abdominal calcification in cystic fibrosis with meconium ileus: radiologic-pathologic correlation. Pediatr Radiol. 1997;27:523–527.
35. Delpin CA, Czyrko C, Ziegler MM, et al. Management and survival of meconium ileus—A 30-year review. Ann Surg. 1992;215:179–185.
36. Colombo C, Ellemunter H, Houwen R, et al. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. J Cyst Fibros. 2011;10:S24–S28.
37. Dray X, Bienvenu T, Desmazes-Dufeu N, et al. Distal intestinal obstruction syndrome in adults with cystic fibrosis. Clin Gastroenterol Hepatol. 2004;2:498–503.
38. Houwen RH, van der Doef HP, Sermet I, et al. Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS. J Pediatr Gastroenterol Nutr. 2010;50:38–42.
39. Brown NJ, Read NW, Richardson A, et al. Characteristics of lipid substances activating the ileal brake in the rat. Gut. 1990;31:1126–1129.
40. van der Doef HP, Kokke FT, van der Ent CK, et al. Intestinal obstruction syndromes in cystic fibrosis: meconium ileus, distal. Curr Gastroenterol Rep. 2011;13:265–270.
41. Stern RC, Izant RJ, Boat TF, et al. Treatment and prognosis of rectal prolapse in cystic-fibrosis. Gastroenterology. 1982;82:707–710.
42. Siafakas C, Vottler TP, Andersen JM. Rectal prolapse in pediatrics. Clin Pediatr. 1999;38:63–72.
43. Nash EF, Stephenson A, Helm EJ, et al. Intussusception in adults with cystic fibrosis: a case series with review of the literature. Dig Dis Sci. 2011;56:3695–3700.
44. Munck A, Belarbi N, de Lagausie P, et al. Ultrasonography detects appendicular mucocele in cystic fibrosis patients suffering recurrent abdominal pain. Pediatrics. 2000;105:921.
45. Coughlin JP, Gauderer MWL, Stern RC, et al. The spectrum of appendiceal disease in cystic fibrosis. J Pediatr Surg. 1990;25:835–839.
46. Lardenoye SW, Puylaert JB, Smit MJ, et al. Appendix in children with cystic fibrosis: US features. Radiology. 2004;232:187–189.
47. Chaun H. Colonic disorders in adult cystic fibrosis. Can J Gastroenterol. 2001;15:586–590.
48. Smyth RL, Vanvelzen D, Smyth AR, et al. Strictures of ascending colon in cystic fibrosis and high-strength pancreatic-enzymes. Lancet. 1994;343:85–86.
49. Smyth RL, Ashby D, Ohea U, et al. Fibrosing colonopathy in cystic fibrosis—results of a case-control study. Lancet. 1995;346:1247–1251.
50. Moss RL, Musemeche CA, Feddersen RM. Progressive pan-colonic fibrosis secondary to oral administration of pancreatic enzymes. Pediatr Surg Int. 1998;13:168–170.
51. Schneider ARJ, Klueber S, Posselt HG, et al. Application of the glucose hydrogen breath test for the detection of bacterial overgrowth in patients with cystic fibrosis–a reliable method? Dig Dis Sci. 2009;54:1730–1735.
52. Neglia JP, FitzSimmons SC, Maisonneuve P, et al. The risk of cancer among patients with cystic fibrosis. Cystic fibrosis and cancer study group. N Engl J Med. 1995;332:494–499.
53. Meyer KC, Francois ML, Thomas HK, et al. Colon cancer in lung transplant recipients with CF: increased risk and results of screening. J Cyst Fibros. 2011;10:366–369.
54. Feranchak AP. Hepatobiliary complications of cystic fibrosis. Curr Gastroenterol Rep. 2004;6:231–239.
55. Sokol RJ, Durie PR. Cystic Fibrosis Fdn Hepatobiliary Dis C. Recommendations for management of liver and biliary tract disease in cystic fibrosis. J Pediatr Gastroenterol Nutr. 1999;28:S1–S13.
56. Colombo C. Liver disease in cystic fibrosis. Curr Opin Pulm Med. 2007;13:529–536.
57. Cohn JA, Strong TV, Picciotto MR, et al. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology. 1993;105:1857–1864.
58. Kochar R, Fallon MB. Pulmonary diseases and the liver. Clin Liver Dis. 2011;15:21.
59. Herrmann U, Dockter G, Lammert F. Cystic fibrosis-associated liver disease. Best Pract Res Clin Gastroenterol. 2010;24:585–592.
60. Lewindon PJ, Pereira TN, Hoskins AC, et al. The role of hepatic stellate cells and transforming growth factor-beta(1) in cystic fibrosis liver disease. Am J Pathol. 2002;160:1705–1715.
61. Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology. 1999;30:1151–1158.
62. Colombo C, Battezzati PM, Crosignani A, et al. Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology. 2002;36:1374–1382.
63. Bartlett JR, Friedman KJ, Ling SC, et al. Genetic modifiers of liver disease in cystic fibrosis. J Am Med Assoc. 2009;302:1076–1083.
64. Lindblad A, Glaumann H, Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology. 1998;27:166–174.
65. Colombo C, Crosignani A, Assaisso M, et al. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study. Hepatology. 1992;16:924–930.
66. Colombo C, Battezzati PM, Podda M, et al. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-mind multicenter trial. Hepatology. 1996;23:1484–1490.
67. Cheng K, Ashby D, Smyth RL. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev. 2012;10:CD000222.
68. Imam MH, Sinakos E, Gossard AA, et al. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther. 2011;34:1185–1192.
69. Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50:808–814.
70. Lu BR, Esquivel CO. A review of abdominal organ transplantation in cystic fibrosis. Pediatr Transpl. 2010;14:954–960.
71. Molmenti EP, Squires RH, Nagata D, et al. Liver transplantation for cholestasis associated with cystic fibrosis in the pediatric population. Pediatr Transpl. 2003;7:93–97.
72. Enriquez G, Lucaya J, Allende E, et al. Intrahepatic biliary stone in children. Pediatr Radiol. 1992;22:283–286.
73. Gaskin KJ, Waters DLM, Howmangiles R, et al. Liver disease and common-bile-duct stenosis in cystic fibrosis. N Engl J Med. 1988;318:340–346.
74. Perdue DG, Cass OW, Milla C, et al. Hepatolithiasis and Cholangiocarcinoma in cystic fibrosis: a case series and review of the literature. Dig Dis Sci. 2007;52:2638–2642.
75. Bass S, Connon JJ, Ho CS. Biliary tree in cystic fibrosis: biliary tract abnormalities in cystic fibrosis demonstrated by endoscopic retrograde cholangiography. Gastroenterology. 1983;84:1592–1596.
76. Baldwin TL, Schutz SM, Owens G, et al. Successful endoscopic therapy of cholangitis associated with intrahepatic cholangiectasis in adult cystic fibrosis. Gastrointest Endosc. 1999;49:249–251.
77. Lo CM, Fan ST, Wong J. The changing epidemiology of recurrent pyogenic cholangitis. Hong Kong Med J. 1997;3:302–304.
78. Ong GB. A study of recurrent pyogenic cholangitis. Arch Surg. 1962;84:199–225.
79. Wasmuth HE, Keppeler H, Herrmann U, et al. Coinheritance of Gilbert syndrome-associated UGT1A1 mutation increases gallstone risk in cystic fibrosis. Hepatology. 2006;43:738–741.
80. Karlas T, Neuschulz M, Oltmanns A, et al. Non-invasive evaluation of cystic fibrosis related liver disease in adults with ARFI, transient elastography and different fibrosis scores. Plos One. 2012;7:8.
81. Treem WR, Stanley CA. Massive hepatomegaly, steatosis, and secondary plasma carnitine deficiency in an infant with cystic fibrosis. Pediatrics. 1989;83:993–997.
82. Aldamiz-Echevarria L, Prieto J, Andrade F, et al. Persistence of essential fatty acid deficiency in cystic fibrosis despite nutritional therapy. Pediatr Res. 2009;66:585–589.
83. Freedman SD, Shea JC, Blanco PG, et al. Fatty acids in cystic fibrosis. Curr Opin Pulm Med. 2000;6:530–532.
84. Colombo C, Bertolini E, Assaisso ML, et al. Failure of ursodeoxycholic acid to dissolve radiolucent gallstones in patients with cystic fibrosis. Acta Paediatr. 1993;82:562–565.
85. Angelico M, Gandin C, Canuzzi P, et al. Gallstones in cystic fibrosis: a critical reappraisal. Hepatology. 1991;14:768–775.
86. Roy CC, Weber AM, Morin CL, et al. Abnormal biliary lipid composition in cystic fibrosis: effect of pancreatic enzymes. N Engl J Med. 1977;297:1301–1305.